Navigation Links
European Medicines Agency accepts marketing authorization application for Boehringer Ingelheim and Eli Lilly and Company's empagliflozin*, an investigational type 2 diabetes treatment

RIDGEFIELD, Conn. and INDIANAPOLIS, March 26, 2013 /PRNewswire/ -- Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced the European Medicines Agency (EMA) has accepted for review a marketing authorization application (MAA) for the investigational sodium glucose co-transporter-2 (SGLT2) inhibitor empagliflozin*, for the treatment of type 2 diabetes mellitus (T2D) in adults. The acceptance of the MAA marks the beginning of the review process in the European Union for this potential oral diabetes treatment.

"We are pleased the EMA has accepted our marketing authorization application for a potential new treatment option to help patients better manage their type 2 diabetes mellitus," said Prof. Klaus Dugi, Corporate Senior Vice President Medicine, Boehringer Ingelheim. "More than 300 million people worldwide live with type 2 diabetes mellitus and varied approaches to treating this condition are needed to help these patients better manage their condition."

A New Drug Application for empagliflozin was recently submitted to the Food and Drug Administration (FDA) in the United States for the treatment of T2D in adults.

Empagliflozin is a member of the SGLT2 inhibitor class of drugs being investigated for the reduction of blood glucose levels in adults with T2D. The emerging SGLT2 inhibitor class removes excess glucose through the urine by blocking glucose re-absorption in the kidney.

About Diabetes

Approximately 25.8 million Americans[1] and an estimated 371 million people worldwide[2] have type 1 or type 2 diabetes. T2D is the most common type, accounting for an estimated 90 percent of all diabetes cases.[2] Diabetes is a chronic disease that occurs when the body either does not properly produce, or use, the hormone insulin.[3] Diabetes was estimated to cost the U.S. $245 billion in direct medical costs and reduced productivity in 2012.[4]

Boehringer Ingelheim and Eli Lilly and Company

In January 2011, Boehringer Ingelheim and Eli Lilly and Company announced an alliance in the field of diabetes that centers on three pipeline compounds representing several of the largest treatment classes. This alliance leverages the companies' strengths as two of the world's leading pharmaceutical companies, combining Boehringer Ingelheim's solid track record of research-driven innovation and Lilly's innovative research, experience, and pioneering history in diabetes. By joining forces, the companies demonstrate commitment in the care of patients with diabetes and stand together to focus on patient needs. Find out more about the alliance at or

About Boehringer Ingelheim

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 44,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.

As a central element of its culture, Boehringer Ingelheim pledges to act socially responsibly. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim's endeavors.

In 2011, Boehringer Ingelheim achieved net sales of about $17.1 billion (13.2 billion euro). R&D expenditure in the business area Prescription Medicines corresponds to 23.5% of its net sales.

For more information, please visit and follow us on Twitter at

About Eli Lilly and Company

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, IN, Lilly provides answers – through medicines and information – for some of the world's most urgent medical needs. Additional information about Lilly is available at

About Lilly Diabetes

Lilly has been a global leader in diabetes care since 1923, when we introduced the world's first commercial insulin. Today we work to meet the diverse needs of people with diabetes through research and collaboration, a broad and growing product portfolio and our continued commitment to providing real solutions – from medicines to support programs and more – to make lives better.

For more information, visit

This press release contains forward-looking statements about empagliflozin* for the treatment of type 2 diabetes. It reflects Lilly's current beliefs; however, as with any such undertaking, there are substantial risks and uncertainties in the process of drug development and commercialization. There is no guarantee that future study results and patient experience will be consistent with study findings to date or that empagliflozin* will prove to be commercially successful. For further discussion of these and other risks and uncertainties, please see Lilly's latest Forms 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Lilly undertakes no duty to update forward-looking statements.

*Empagliflozin is an investigational compound. Its safety and efficacy have not yet been fully established.

[1] Centers for Disease Control and Prevention. National Diabetes Fact Sheet: National Estimates and General Information on Diabetes and Prediabetes in the United States, 2011. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2011.

[2] International Diabetes Federation. IDF Diabetes Atlas Poster. 2012 Update. 2012 (5th Edition).

[3] International Diabetes Federation. IDF Diabetes Atlas, 5th Edition: What is Diabetes? Accessed on: March 21, 2013

[4] American Diabetes Association. Economic costs of diabetes in the U.S. in 2012. Diabetes Care. 2013. Mar 6. [Epub ahead of print]


Catherine London
Associate Director, Communications and Public Relations
Boehringer Ingelheim Pharmaceuticals, Inc.
Phone: (203) 798-4638

Tammy Hull
Communications Manager
Lilly Diabetes
Phone: (317) 651-9116

(Logo: )
(Logo: )

SOURCE Eli Lilly and Company; Boehringer Ingelheim
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Genalyte Announces CE Mark For Maverick(TM) Detection System And Signs On First European Distributors
2. European Commission Designates MST-188 As An Orphan Medicinal Product
3. Baxter And Halozyme Announce Positive Opinion For HyQvia For Treatment Of Primary And Secondary Immunodeficiencies In The European Union
4. Surveyed U.S. and European Neurologists Agree that a Therapys Effect on Physical Disability is the Most Important Attribute Influencing Prescribing Decisions in Secondary-Progressive Multiple Sclerosis
5. SonaCare Medical to Introduce Two New HIFU Products at the European Association of Urology (EAU) Congress
6. European Hearing Aids and Audiology Devices Market
7. Takeda Submits Marketing Authorisation Application for Vedolizumab in Moderately to Severely Active Ulcerative Colitis and Crohns Disease in the European Union
8. Product Differentiation to Boost European Human Growth Hormones Market, Says Frost & Sullivan
9. BioElectronics Expands European Distribution to Malta
10. Heptares to Present at the 6th Annual European Life Sciences CEO Forum (5-6 March)
11. Cardica Updates Enrollment Progress In European Clinical Trial
Post Your Comments:
(Date:11/30/2015)... 2015   Royal Philips (NYSE: PHG ... first MRI guided user interface and automatic scan parameter ... MR Conditional implants, such as knee and hip replacements, ... Society of North America Annual Meeting (RSNA) . The ... confidence of this growing patient population. ScanWise Implant adds ...
(Date:11/30/2015)... -- North America was valued at ... a CAGR of 7.6% from 2015 to 2020. --> ... in 2014, and is expected to grow at a CAGR of ... new Market Research Report "North America Cardiac Output Monitoring Devices Market ... care, others) - Analysis And Forecast To 2020", the cardiac output ...
(Date:11/30/2015)... KONG, Nov. 30, 2015 (HK$,000)For the Six Months Ended 30 September 2015 ... Income , 421,979 , 384,242 , ... , 34,719 , (18.3) Medical Insurance ... , 16.1 Medical Devices and Accessories Sales , ... Chinese Herbal Medicines Sales , 2,822 , ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... November 30, 2015 , ... According to an article published ... but slightly unusual choice to show her Instagram followers that the praise that they ... been pre-mature. Saying that she didn’t “want to mislead any mommy's who just had ...
(Date:11/30/2015)... Los Angeles, CA (PRWEB) , ... November 30, 2015 , ... ... hunger cravings that drive people to overeat are not necessarily caused by real hunger, ... brain that the stomach needs food. He notes that, while many patients are aware ...
(Date:11/30/2015)... ... November 30, 2015 , ... Cycling, running, and walking ... on extra meaning the morning of February 28, 2016. , That’s when the ... and thousands will exercise to help children and families at Joe DiMaggio Children’s ...
(Date:11/30/2015)... ... November 30, 2015 , ... RoamRight, a leading provider of travel ... Public Television’s Travel With Kids to promote family vacations around the world. The ... explore international destinations and educate families about the people and places of the world, ...
(Date:11/30/2015)... ... November 30, 2015 , ... A novel class of ... be effective in fighting methicillin-resistant Staphylococcus aureus (MRSA), one of the major drug-resistant ... that small molecule analogs that target the functions of SecA, a central part ...
Breaking Medicine News(10 mins):